

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Colon cancer	Parkin (PARK2)	<p>Human tissue and mouse studies suggest that increasing PARK2 expression could help treat colon cancer. PARK2 DNA copy numbers were increased in about one-third of tissue samples from 100 primary colorectal cancer patients. In an analysis of transcriptional profiles, lower PARK2 expression correlated with lower expression of <i>adenomatous polyposis coli</i> (<i>APC</i>; $p < 0.001$), a gene often mutated in colorectal cancers. In mice expressing mutant <i>Apc</i>, heterozygous <i>Park2</i> knockout led to greater adenocarcinoma than normal <i>Park2</i> expression ($p < 0.0001$). Next steps could include developing a strategy for increasing PARK2 expression.</p> <p>SciBX 3(33); doi:10.1038/scibx.2010.1008 Published online Aug. 26, 2010</p>	Patent and licensing status unavailable	<p>Poulogiannis, G. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Aug. 9, 2010; doi:10.1073/pnas.1009941107 Contact: Mark J. Arends, University of Cambridge, Cambridge, U.K. e-mail: mja40@cam.ac.uk</p>